Delayed adjuvant endocrine therapy is associated with decreased recurrence-free survival following neoadjuvant chemotherapy for breast cancer - 02/05/23
Abstract |
Background |
In hormone receptor-positive breast cancer (HRPBC), endocrine therapy is often initiated after adjuvant radiotherapy given concerns of radiation fibrosis. No studies have investigated how this may impact outcomes in high-risk patients undergoing neoadjuvant chemotherapy (NAC).
Methods |
Females with nonmetastatic HRPBC receiving NAC from 2011 to 2017 were identified from our multi-institutional database. Interval from surgery to endocrine therapy (ISET) was calculated in weeks. Recurrence-free survival (RFS) and overall survival (OS) were evaluated with Kaplan-Meier and Cox proportional hazards modeling.
Results |
Of 280 patients, 179 (64%) received adjuvant radiotherapy; all deaths (n = 25) and 90% (n = 27) of recurrences occurred in this group, which was the focus of subsequent analysis.
Median follow-up was 49 months. Recurrences were predominantly distant metastases (n = 21, 81%). Median ISET was 12 weeks (range 0–55 weeks). On multivariable analysis, ISET >14 weeks was independently associated with worse RFS (HR 3.20, 95% C.I. 1.22–8.40, P = 0.02) but not OS (HR 2.15, 95% C.I. 0.75–6.15, P = 0.15).
Conclusion |
In patients with HRPBC treated with NAC and adjuvant radiation, increasing ISET is associated with adverse oncologic outcomes.
Le texte complet de cet article est disponible en PDF.Highlights |
• | In high-risk breast cancer, longer time from surgery to endocrine therapy was associated with worse recurrence-free survival. |
• | High-risk patients may benefit from early systemic endocrine therapy, and delays may have negative oncologic consequences. |
• | Delaying endocrine therapy in patients receiving radiotherapy should be carefully considered, weighing patient risk factors |
Keywords : Breast cancer, Neoadjuvant chemotherapy, Radiotherapy, Endocrine therapy, Treatment sequencing, Oncologic outcomes
Plan
Vol 225 - N° 5
P. 861-865 - mai 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?